Wake Forest University, Winston Salem
Adverse outcomes in Childhood Cancer Survivor Study (CCSS) not associated with minority status
Published in Pharma Investments, Ventures and Law Weekly, December 18th, 2005
Researchers in the United States conducted a study "to determine the influence of race/ethnicity on outcomes in the CCSS. Of CCSS adult survivors in the United States, 443 (4.9%) were black, 503 (5.6%) were Hispanic and 7,821 (86.6%) were white. Mean age at interview, 26.9 years (range, 18 to 48 years); mean follow-up, 17.2 years (range, 8.7 to 28.4 years)."
"Late mortality, second malignancy (SMN) rates, health care utilization, and health status and behaviors were assessed for blacks and Hispanics and compared with white survivors....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- A.P. Pharma, Inc.
Developer of polymer-based drug delivery systems evaluating financing options - Aastrom Biosciences, Inc
Stem cell therapy developer reports net loss of $0.03 per share - Aceto Corp.
Chemically derived drug maker reports $5.4M decline in sales - Acusphere, Inc.
Microparticle drug developer reports on operational progress - Advanced BioPhotonics, Inc.
Medical imaging developer obtains $4M financing - Advanced Magnetics, Inc.
Nanotechnology company reports loss of $0.36 per share - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
